Drug makers may face limits on anemia drugs
Drug makers Amgen and Johnson & Johnson may be forced to limit the targeted patient population and dosing levels for popular anti-anemia drugs to reduce risks to cancer patients. Safety concerns have slowed the growth of the drugs already after the FDA raised concerns about the drugs. The level of the drugs prescribed has the risk of increasing patients’ risks of heart attacks or strokes.
For the full article.
Bookmark: 
